HDL and chronic kidney disease

Abstract

Low HDL-cholesterol (HDL-C) concentrations are a typical trait of the dyslipidemia associated with chronic kidney disease (CKD). In this condition, plasma HDLs are characterized by alterations in structure and function, and these particles can lose their atheroprotective functions, e.g., the ability to promote cholesterol efflux from peripheral cells, anti-oxidant and anti-inflammatory proprieties and they can even become dysfunctional, i.e., exactly damaging. The reduction in plasma HDL-C levels appears to be the only lipid alteration clearly linked to the progression of renal disease in CKD patients. The association between the HDL system and CKD development and progression is also supported by the presence of genetic kidney alterations linked to HDL metabolism, including mutations in the APOA1, APOE, APOL and LCAT genes. Among these, renal disease associated with LCAT deficiency is well characterized and lipid abnormalities detected in LCAT deficiency carriers mirror the ones observed in CKD patients, being present also in acquired LCAT deficiency. This review summarizes the major alterations in HDL structure and function in CKD and how genetic alterations in HDL metabolism can be linked to kidney dysfunction. Finally, the possibility of targeting the HDL system as possible strategy to slow CKD progression is reviewed.

Keywords: Chronic kidney disease; HDL; LCAT.

Fig. 1

Summary of the main changes in HDL subclasses (A) and structural and compositional changes (B) in chronic kidney disease. ApoA-I, apolipoprotein A-I; apoA-II, apolipoprotein A-II; apoM, apolipoprotein M; apoA-IV, apolipoprotein A-IV; apoC-II, apolipoprotein C-II; apoC-III, apolipoprotein C-III; LCAT, lecithin:cholesterol acyltransferase. Lp-PLA2, lipoprotein-associated phospholipase A2; PL, phospholipids; PON-1, paraoxonase-1; SAA, serum amyloid A; SP-B, surfactant protein B; TG, triglycerides.

Fig. 2

Potential therapeutic approaches for CKD targeting HDL metabolism. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; apoA-I, apolipoprotein A-I; CE, cholesteryl esters; CETP, cholesteryl ester transfer protein; LCAT, lecithin:cholesterol acyltransferase; SR-BI, scavenger receptor BI; TG, triglycerides.